(Q35576166)

8 August 2017

1 reference

title

Update on the treatment of neuroendocrine tumors (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

28 March 2024

author name string

Emilio Bajetta

1

1 reference

8 August 2017

Giuseppe Procopio

2

1 reference

8 August 2017

Leonardo Ferrari

3

1 reference

8 August 2017

Laura Catena

4

1 reference

8 August 2017

Michele Del Vecchio

5

1 reference

8 August 2017

Emilio Bombardieri

6

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14599087

28 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1586/14737140.3.5.631

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Expert Review of Anticancer Therapy

28 March 2024

published in

1 reference

8 August 2017

volume

3

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

631-642

1 reference

Molecular genetics of neuroendocrine tumors

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Hepatic surgery for metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

The somatostatin receptor family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.5.631

Growth characteristics of rectal carcinoid tumors

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors

28 March 2024

12

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours.

28 March 2024

14

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors

28 March 2024

16

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

28 March 2024

26

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine

28 March 2024

28

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Somatuline Autogel: an extended release lanreotide formulation.

28 March 2024

38

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Interferons in the treatment of human cancer

28 March 2024

45

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Adverse reactions in long-term interferon treatment

28 March 2024

46

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial

28 March 2024

49

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Yttrium-90-labelled somatostatin-analogue for cancer treatment

28 March 2024

50

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors

28 March 2024

65

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

28 March 2024

70

1 reference

https://api.crossref.org/works/10.1586/14737140.3.5.631

28 March 2024

Identifiers

1 reference

8 August 2017

1 reference